Post-Operative Cataract Surgery Inflammation Treatment Market Report 2026

Post-Operative Cataract Surgery Inflammation Treatment Market Overview

• Post-Operative Cataract Surgery Inflammation Treatment market size has reached to $4.78 billion in 2025 • Expected to grow to $6.78 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Rise In Traumatic Injuries Driving The Market • Market Trend: Innovations In Postoperative Ocular Analgesics Enhance Relief Of Pain And Inflammation Following Cataract Surgery • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Post-Operative Cataract Surgery Inflammation Treatment Market?

Post-operative cataract surgery inflammation treatment refers to the medical interventions aimed at managing inflammation and discomfort after cataract surgery. These medications aim to control inflammation, prevent complications such as rebound iritis and pseudophakic cystoid macular edema (PCME), and promote faster recovery. The main drug classes of post-operative cataract surgery inflammation treatment are bromfenac, indomethacin, diclofenac, flurbiprofen, and nepafenac. Bromfenac is a potent NSAID used in ophthalmology to reduce post-operative inflammation and pain by inhibiting COX-1 and COX-2 enzymes. These drugs are administered through various routes, including oral and injectable, and are distributed through multiple channels, such as hospital pharmacies, online pharmacies, and retail pharmacies.

What Is The Post-Operative Cataract Surgery Inflammation Treatment Market Growth Forecast?

The post-operative cataract surgery inflammation treatment market size is expected to see strong growth in the next few years. It will grow to $6.78 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing demand for advanced ophthalmic formulations, rising focus on reducing post-operative complications, expansion of minimally invasive eye surgeries, growing investments in ophthalmology research, increasing adoption of patient-specific treatment regimens. Major trends in the forecast period include increasing use of combination anti-inflammatory therapies, rising adoption of ophthalmic nsaids, growing focus on faster post-surgical recovery, expansion of hospital-based ophthalmic care protocols, enhanced emphasis on preventing post-surgical complications.

Global Post-Operative Cataract Surgery Inflammation Treatment Market Segmentation

1) By Drug Class: Bromfenac, Indomethacin, Diclofenac, Flurbiprofen, Nepafenac 2) By Route of Administration: Topical Ophthalmic, Intracameral And Ophthalmic Use 3) By Distribution Channel: Hospital pharmacy, Online Pharmacy, Retail pharmacy Subsegments: 1) By Bromfenac: Bromfenac Ophthalmic Solution 0.07%, Bromfenac Ophthalmic Solution 0.09%, Combination Therapies With Bromfenac 2) By Indomethacin: Indomethacin Ophthalmic Solution 0.1%, Indomethacin Ophthalmic NSAID Formulations, Ophthalmic Anti-Inflammatory Solutions 3) By Diclofenac: Diclofenac Ophthalmic Solution 0.1%, Diclofenac Ophthalmic Drops, Ophthalmic NSAID Preparations 4) By Flurbiprofen: Flurbiprofen Ophthalmic Solution 0.03%, Adjunctive Use In Ocular Surgery, Combination Therapies With Flurbiprofen 5) By Nepafenac: Nepafenac Ophthalmic Suspension 0.1%, Nepafenac Ophthalmic Suspension 0.3%

What Is The Driver Of The Post-Operative Cataract Surgery Inflammation Treatment Market?

The rise in traumatic injuries is expected to propel the growth of the post-operative cataract surgery inflammation treatment market going forward. Traumatic injuries are sudden physical injuries caused by external forces such as accidents, falls, violence, or sports impacts, ranging from minor cuts to severe fractures, burns, brain injuries, and spinal damage. A rise in traumatic injuries can be attributed to factors such as increased road traffic accidents, workplace hazards, sports-related incidents, violence, natural disasters, and aging populations prone to falls. Post-operative cataract surgery inflammation treatment helps traumatic injuries by reducing ocular inflammation, minimizing pain, and preventing complications that could impair visual recovery. For instance, in October 2024, according to the Insideworldfootball, a UK-based web-based news-driven service, sports injuries reached a total of 4,123 during the 2023-24 season, marking a 4% increase compared to the 2022-23. Therefore, the rise in traumatic injuries is driving the growth of the post-operative cataract surgery inflammation treatments industry.

Key Players In The Global Post-Operative Cataract Surgery Inflammation Treatment Market

Major companies operating in the post-operative cataract surgery inflammation treatment market are Alcon Inc, Bausch & Lomb Incorporated, Santen Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Merck & Co. Inc., Sun Pharmaceutical Industries Limited, EyePoint Pharmaceuticals Inc, Ocular Therapeutix Inc., Oculis Holding AG, Senju Pharmaceutical Co. Ltd., Nicox S.A., Formosa Pharmaceuticals Inc, Eyenovia Inc., Surface Ophthalmics Inc., ImprimisRx LLC, NTC Srl, VivaVision Biotech Inc., Bio-Tissue Inc., Mallinckrodt plc

Global Post-Operative Cataract Surgery Inflammation Treatment Market Trends and Insights

Major companies operating in the post-operative cataract surgery inflammation treatment market are focusing on developing innovative therapies, such as postoperative ocular analgesics, to enhance the relief of pain and inflammation following ocular surgery. Postoperative ocular analgesics refer to therapeutic agents specifically designed to alleviate pain and reduce inflammation in the eye after surgical procedures, thereby promoting patient comfort and supporting optimal recovery outcomes. For instance, in March 2024, Formosa Pharmaceuticals, a Taiwan-based pharmaceutical company in collaboration with AimMax Therapeutics, a US-based biotechnology company, received FDA approval for clobetasol propionate ophthalmic suspension 0.05% (APP13007) for the treatment of post-operative pain and inflammation following ocular surgery. APP13007 is the first ophthalmic clobetasol propionate product approved by the FDA and marks the introduction of the first new ophthalmic steroid on the market in over 15 years, offering a novel option to manage post-operative ocular inflammation and enhance patient recovery.

What Are Latest Mergers And Acquisitions In The Post-Operative Cataract Surgery Inflammation Treatment Market?

In September 2024, Armistice Capital LLC, a US-based home health care service company, acquired Eyenovia Inc. for an undisclosed amount. With this acquisition, Armistice Capital LLC aims to leverage its increased stake in Eyenovia to influence the company's strategic direction and capitalize on potential future growth in the ophthalmic sector. Eyenovia Inc. is a US-based pharmaceutical company that treats post-operative inflammation and pain after ocular surgery with clobetasol.

Regional Outlook

North America was the largest region in the post-operative cataract surgery inflammation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Post-Operative Cataract Surgery Inflammation Treatment Market?

The post-operative cataract surgery inflammation treatment market consists of sales of corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and anti-inflammatory medications. Values in this market are 'factory gate' values, meaning the value of goods sold by manufacturers, whether to other entities (including wholesalers, distributors, or directly to end customers) or downstream manufacturers. The value of goods includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Post-Operative Cataract Surgery Inflammation Treatment Market Report 2026?

The post-operative cataract surgery inflammation treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the post-operative cataract surgery inflammation treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.